Last updated 2 months ago

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

1080 patients around the world
Available in Mexico
Summit Therapeutics
1080Patients around the world

This study is for people with

Lung cancer
Non-small cell lung carcinoma

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Age ≥ 18 years old at the time of enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Expected life expectancy ≥ 3 months.
Metastatic (Stage IV) NSCLC.
Histologically or cytologically confirmed squamous or non-squamous NSCLC.
Recorded measurement of the Tumor Proportion Score (TPS) for PD-L1 expression, irrespective of the PD-L1 expression, prior to randomization.
At least one measurable noncerebral lesion according to RECIST 1.1.
No prior systemic treatment for metastatic NSCLC.
Histologic or cytopathologic evidence of the presence of small cell lung carcinoma.
Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.
For non-squamous histology patients, actionable driver mutation testing results are required before randomization.
Has received any prior therapy for NSCLC in the metastatic setting.
Tumor invasion, encasement of organs (e.g. heart, trachea, esophagus, central bronchi), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding.
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy